Document ID: chunk:federal_register_of_legislation:F2024L01524:schedule:1:p1
Version: federal_register_of_legislation:F2024L01524
Segment Type: schedule
Provision Reference: sch 1 (pt 1/38)
Character Range: 2134–5106

Schedule 1—Amendments

National Health (Listing of Pharmaceutical Benefits) Instrument 2024 (PB 26 of 2024)
[1] Schedule 1, Part 1, after entry for Abemaciclib in the form Tablet 150 mg
insert:
Abiraterone  Tablet containing abiraterone acetate 250 mg  Oral  Abiraterone-Teva  TB  MP  C13945     120  2     120

[2] Schedule 1, Part 1, after entry for Abiraterone in the form Tablet containing abiraterone acetate 250 mg [Brand: Zytiga]
insert:
Abiraterone  Tablet containing abiraterone acetate 500 mg  Oral  Abiraterone-Teva  TB  MP  C13945     60  2     60

[3] Schedule 1, Part 1, entry for Ambrisentan in the form Tablet 5 mg [Brand: Cipla Ambrisentan]
omit from the column headed "Responsible Person": LR substitute: ZU
[4] Schedule 1, Part 1, entry for Ambrisentan in the form Tablet 10 mg [Brand: Cipla Ambrisentan]
omit from the column headed "Responsible Person": LR substitute: ZU
[5] Schedule 1, Part 1, after entry for Atorvastatin in the form Tablet 80 mg (as calcium) [Brand: Trovas; Maximum Quantity: 60; Number of Repeats: 5]
insert:
Atovaquone  Oral suspension 750 mg per 5 mL, 210 mL  Oral  ATOVACUE  JM  MP NP  C5609     1  0     1

[6] Schedule 1, Part 1, after entry for Beclometasone with formoterol and glycopyrronium in the form Pressurised inhalation containing beclometasone dipropionate 200 micrograms with formoterol fumarate dihydrate 6 micrograms and glycopyrronium 10 micrograms (as bromide) per dose, 120 doses
insert:
Belzutifan  Tablet 40 mg  Oral  Welireg  MK  MP  C16180 C16208 C16215     90  5     90

[7] Schedule 1, Part 1, entries for Bortezomib in the form Powder for injection 3.5 mg
omit:
Bortezomib  Powder for injection 3.5 mg  Injection  BORTEZOMIB-TEVA  TB  MP  C11099 C13745     See Note 3  See Note 3     1     D(100)

[8] Schedule 1, Part 1, after entry for Cabazitaxel in the form Solution concentrate for I.V. infusion 60 mg in 6 mL [Brand: Cabazitaxel Ever Pharma]
insert:
Cabergoline  Tablet 500 micrograms  Oral  Dostamine  NB  MP  C5136 C5137 C5357 C5398      P5136 P5137 P5357 P5398      8   5     8
Cabergoline  Tablet 500 micrograms  Oral  Dostamine  NB  MP  C14918 C14959 C14983 C15005  P14918 P14959 P14983 P15005  16  5     8

[9] Schedule 1, Part 1, entries for Carbamazepine in the forms: Tablet 200 mg (controlled release); and Tablet 400 mg (controlled release)
substitute:
Carbamazepine  Tablet 200 mg (controlled release)  Oral  Tegretol CR 200  NV  PDP               200  0     100
Carbamazepine  Tablet 200 mg (controlled release)  Oral  Tegretol CR 200  NV  PDP               200  0     200
Carbamazepine  Tablet 200 mg (controlled release)  Oral  Tegretol CR 200  NV  MP NP             200  2     100
Carbamazepine  Tablet 200 mg (controlled release)  Oral  Tegretol CR 200  NV  MP NP             200  2     200
Carbamazepine  Tablet 200 mg (controlled release)  Oral  Tegretol CR 200  NV  MP NP     P14238  400  2     100
Carbamazepine  Tablet 200 mg (controlled release)  Oral  Tegretol CR 200  NV